Patents by Inventor Jag Paul Heer

Jag Paul Heer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES
    Publication number: 20240092773
    Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 21, 2024
    Inventors: Timothy John NORMAN, Zhaoning ZHU, Selvaratnam SUGANTHAN, Konstantinos RAMPALAKO, James MADDEN, Jag Paul HEER, Richard Jeremy FRANKLIN, Rickki Lee CONNELLY, Thierry DEMAUDE, Gregory William HASLETT, Benedicte LALLEMAND, Nathaniel Julius Thomas MONCK, Julian Hugh ROWLEY, Giancarlo TRANI
  • Fused pentacyclic imidazole derivatives
    Patent number: 11912721
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 27, 2024
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS
    Publication number: 20230303517
    Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: September 28, 2023
    Inventors: Timothy John NORMAN, Douglas BYRNE, Julian Hugh ROWLEY, Giancarlo TRANI, Konstantinos RAMPALAKOS, Nathaniel Julius Thomas MONCK, Benedicte LALLEMAND, Gregory William HASLETT, Rickki Lee CONNELLY, Jag Paul HEER, James MADDEN, Oliver PHILPS, Selvaratnam SUGANTHAN, Zeshan YOUSUF, Richard John MEARS
  • DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES
    Publication number: 20230192646
    Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 22, 2023
    Inventors: Timothy John NORMAN, Jag Paul HEER, Oliver PHILPS, William Ross PITT, James MADDEN, Zeshan YOUSUF
  • TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS
    Publication number: 20230051300
    Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Timothy John NORMAN, Oliver PHILPS, Gregory William HASLETT, Jag Paul HEER, Giancarlo TRANI
  • TETRAHYDROBENZO-QUINOLINE SULFONAMIDE DERIVATIVES USEFUL AS IGE MODULATORS
    Publication number: 20230050670
    Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (1), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Timothy John NORMAN, Selvaratnam SUGANTHAN, Jag Paul HEER, Zeshan YOUSUF
  • Functionalised Amine Derivatives as IL-17 Modulators
    Publication number: 20220073485
    Abstract: A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 10, 2022
    Inventors: Anne Marie Foley, Jag Paul Heer, Fabien Claude Lecomte, Nathaniel Julius Thomas Monck, Matthew Duncan Selby, Mengyang Xuan, Lihu Yang
  • Fused Pentacyclic Imidazole Derivatives
    Publication number: 20210155637
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 27, 2021
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10953019
    Abstract: A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 23, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Julien Alistair Brown, Daniel Christopher Brookings, Jag Paul Heer, James Andrew Johnson, Zhaoning Zhu
  • Fused pentacyclic imidazole derivatives
    Patent number: 10906919
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 2, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
    Publication number: 20200399268
    Abstract: The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
    Type: Application
    Filed: February 15, 2019
    Publication date: December 24, 2020
    Inventors: Jag Paul Heer, Michal Sarah Hallside, Adam Peter Smalley, Josep Llaveria Cros, Benedicte Lallemand, Martin Alexander Lowe, Xianfu Li, Anthony John Richardson, Robert James Townsend
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10793578
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of f benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 5,7,8,15-tetrahydro-6H-8,15-methanobenzimidazo[1,2-b][2,5]benzodiazocin-6-one derivatives and analogs thereof.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 6, 2020
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Jag Paul Heer, Jean Keyaerts
  • Fused hexacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10766906
    Abstract: Disclosed are substituted fused hexacyclic benzimidazole derivatives of Formula (I) wherein the variables A, B, D, X, M, Q, n, p, q, Z, E, R5, and R12 are defined herein. These compounds are potent modulators of human TNF? activity and of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Teresa De Haro Garcia, Michael Louis Robert Deligny, Jag Paul Heer, Helen Tracey Horsley, Sophie Jadot, Jean Keyaerts
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10669286
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 2, 2020
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer
  • Substituted benzimidazole derivative as a modulator of TNF activity
    Patent number: 10669263
    Abstract: 2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 2, 2020
    Assignee: UCB Biopharma SRL
    Inventor: Jag Paul Heer
  • Fused pentacyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10654861
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 19, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Jean Keyaerts, Luce Elsa Lepissier, Martin Alexander Lowe
  • Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
    Publication number: 20200022988
    Abstract: A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 23, 2020
    Inventors: Julien Alistair Brown, Daniel Christopher Brookings, Jag Paul Heer, James Andrew Johnson, Zhaoning Zhu
  • Fused Pentacyclic Imidazole Derivatives
    Publication number: 20190367535
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 5, 2019
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Fused tricyclic imidazo pyrazines as modulators of TNF activity
    Patent number: 10472362
    Abstract: A series of substituted fused tricyclic imidazo pyrazine derivatives and analoges thereof, represented by formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 12, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Jag Paul Heer, Uwe Heinelt
  • Substituted Benzimidazole Derivative as a Modulator of TNF Activity
    Publication number: 20190284170
    Abstract: 2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: September 19, 2019
    Inventor: Jag Paul Heer